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Carbapenem-resistant Enterobacteriaceae (CRE) are 
emerging as a public health problem in various set-
tings. In Italy, a rapid and remarkable increase of 
carbapenem-non-susceptible Klebsiella pneumoniae 
has been reported since 2010. Here we report on the 
results of a countrywide cross-sectional survey, car-
ried out from 15 May to 30June 2011 to investigate the 
diffusion of CRE in Italy and to characterise the most 
prevalent resistance mechanisms and their dissemina-
tion patterns. CRE were reported from most (23 of 25) 
participating laboratories, with an overall proportion 
of 3.5% and 0.3% among consecutive non-duplicate 
clinical isolates of Enterobacteriaceae from inpatients 
(n=7,154) and outpatients (n=6,595), respectively. 
K. pneumoniae was the most frequent species (propor-
tion of carbapenem-non-susceptible isolates: 11.9%), 
while a minority of CRE of other species were detected. 
Carbapenemase production was detected in the major-
ity (85%) of CRE. KPC-type enzymes were by far the 
most common (89.5% of carbapenemase producers), 
followed by VIM-1 (9.2%) and OXA-48 (1.3%). KPC-
producing K. pneumoniae (KPC-KP) were detected in 
most centres and contributed majorly to the epidemic 
dissemination of CRE recently observed in our coun-
try. Dissemination of KPC-KP was mostly sustained by 
strains of clonal complex 258 (ST-258 producing KPC-2 
or KPC-3, and ST-512 producing KPC-3), while a minor-
ity belonged to ST-101.
Introduction
The increasing resistance to carbapenems among 
Enterobacteriaceae has become a public health prob-
lem of major concern [1,2]. Carbapenem-resistant 
Enterobacteriaceae (CRE) usually exhibit complex mul-
tidrug resistance phenotypes that leave very few thera-
peutic options [3,4], and infections caused by CRE are 
associated with increased morbidity and mortality in 
comparison with those caused by carbapenem-suscep-
tible strains (72% versus 22%) [5].
At least two mechanisms can be responsible for 
acquired carbapenem resistance in Enterobacteriaceae: 
(i) reduced outer membrane permeability by porin loss 
in combination with the production of an extended-
spectrum beta-lactamase (ESBL) or of AmpC-type beta-
lactamase; and (ii) production of beta-lactamases 
capable of hydrolysing carbapenems (carbapenemases) 
[2]. While the former mechanism is a result of muta-
tion and has a low overall propensity to disseminate, 
acquired carbapenemases are encoded by transferable 
genes that can disseminate among different strains 
and different species, and carbapenemase production 
is the leading carbapenem resistance mechanism in 
Enterobacteriaceae [2,6,7]. Several types of acquired 
carbapenemases have been detected in CRE, with 
KPC-, VIM-, NDM- and OXA-48-type enzymes being the 
most prevalent, although with a notable geographical 
variability [2,6-9]. 
In Europe, individual cases or outbreaks of CRE have 
been reported in several countries [6] but data from the 
EARS-NET database show that, until 2009, the propor-
tion of CRE has remained overall low in most countries 
except Greece and Cyprus, where high-level endemicity 
of carbapenem-nonsuscetible Klebsiella pneumoniae 
has been reported since the mid-2000s [10]. In Italy, 
sporadic cases or outbreaks caused by CRE of various 
species and with different resistance mechanisms have 
been reported since the early 2000s [11-24], but only 
since 2010 an abrupt and notable increase in the pro-
portion of carbapenem-non-susceptible K. pneumoniae 
has ben reported by the EARS-NET surveillance system 
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[10]. This trend has recently been confirmed by data 
from the Micronet sentinel surveillance network [25]. 
However, the resistance mechanisms responsible for 
this increase have not been investigated. 
In this work we report the results of a countrywide 
cross-sectional survey promoted by the Italian Society 
of Clinical Microbiologists (AMCLI) and carried out in 
mid-2011, to investigate the diffusion of CRE in Italy 
and to characterise the most prevalent resistance 
mechanisms and their dissemination patterns. Results 
confirmed that CRE have reached epidemic dissemi-
nation in Italy, and revealed that this condition was 
mostly related with the clonal diffusion of K. pneumo-
niae producing KPC-type carbapenemases (KPC-KP) of 
clonal complex (CC) 258.
Methods
Study design
Twenty-five large clinical microbiology laboratories 
from 23 Italian cities, distributed across the national 
territory and covering most Italian regions, participated 
in the study (Figure 1). During the period from 15 May 
to 30 June 2011, each laboratory collected consecutive 
non-replicate clinical isolates of Enterobacteriaceae, 
from any site of infection, that exhibited minimum 
inhibitory concentrations (MICs) for imipenem and/or 
meropenem and/or ertapenem higher than 1 mg/L (for 
isolates of Proteeae, i. e. Morganella morganii, Proteus 
spp. and Providencia spp., only meropenem and ertap-
enem MICs were considered). The collected isolates 
were transferred to reference laboratories for confir-
mation of species identification and carbapenem MICs, 
and for characterisation of the carbapenem resistance 
mechanisms and analysis of clonal relatedness. For 
each isolate, information on the clinical specimen and 
type of ward (in case of isolates from inpatients) were 
provided. Moreover, each participating laboratory pro-
vided information on the total number of consecutive 
non- duplicate clinical isolates of Enterobacteriaceae 
observed during the collection period. 
Characterisation of bacterial isolates 
and of resistance determinants
Bacterial identification and antimicrobial susceptibil-
ity testing were carried out by the collecting laborato-
ries using either the Phoenix Automated Microbiology 
System (Becton Dickinson Diagnostic Systems, Sparks, 
United States) or the Vitek-2 System (bioMérieux, 
Marcy l’Etoile, France). Confirmatory identification was 
carried out by Matrix-assisted laser desorption ionisa-
tion – time of the flight (MALDI-TOF) mass spectrom-
etry (Vitek-MS, bioMérieux). Confirmatory MIC testing 
for imipenem, meropenem and ertapenem was car-
ried out by Etest (bioMérieux). All collected isolates 
confirmed to be non-susceptible to imipenem (not 
considered for Proteeae) and/or meropenem and/or 
ertapenem according to the EUCAST breakpoints [26] 
were considered as CRE for the purposes of this study. 
For KPC-KP, MICs of colistin, tigecycline and gentamicin 
were determined by the reference broth microdilution 
method [27], and results were interpreted according to 
the EUCAST breakpoints [26].
CRE were evaluated for carbapenemase production by 
meropenem plus EDTA and meropenem plus phenylbo-
ronic acid using the disk diffusion method [28,29], and 
for the presence of the most common carbapenemase 
genes (blaKPC-, blaVIM-, blaNDM-, blaOXA-48-type) by dot-
blot hybridisation [30]. PCR amplification [13,31-33] 
and sequencing of PCR amplicons were used to iden-
tify the carbapenemase genes detected by hybridisa-
tion. All CRE isolates testing negative in disk diffusion 
test and/or in hybridisation assays were further inves-
tigated for production of carbapenemase activity by 
modified Hodge test [34] and by spectrophotometric 
assay with crude extracts [35].
Figure 1
Location of the laboratories participating in the survey on 
carbapenem-resistant Enterobacteriaceae, Italy, 15 May–30 
June 2011 (n=25)
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1: Milan; 2: Varese; 3: Lecco; 4: Turin; 5: Novara; 6: Genoa; 7: 
Sanremo; 8: Verona; 9: Bolzano; 10-11: Modena; 12: Florence; 
13: Siena; 14: Perugia; 15: Ancona; 16: Rome; 17: Pescara; 18: 
San Giovanni Rotondo; 19: Lecce; 20: Naples; 21: Avellino; 
22: Cosenza; 23: Palermo; 24-25: Catania. The types of 
carbapenemases detected in different laboratories, and the 
proportion of KPC-producing Klebsiella pneumoniae versus the 
total number of K. pneumoniae isolates are indicated. 
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Analysis of clonal relatedness
Genotyping of K. pneumoniae isolates by pulsed-field 
gel electrophoresis (PFGE) profiling of genomic DNA 
was carried out after digestion with XbaI with a CHEF-
DRIII apparatus (Bio-Rad, Hemel Hempstead, United 
Kingdom) [36], and results interpreted as recommended 
by Van Belkum et al. [37]. Multi-locus sequence typing 
(MLST) of K. pneumoniae isolates was performed as 
previously described [38], and sequence types (STs) 
were assigned using the MLST web site [39].
Results 
Proportions of carbapenem-resistant 
Enterobacteriaceae from inpatients 
and outpatients in Italy
During the study period (15 May–30 June 2011), a total 
of 13,749 consecutive non-replicate clinical isolates of 
Enterobacteriaceae were isolated at the 25 Italian labo-
ratories participating in the survey. Overall, 270 iso-
lates (2.0%) were confirmed as CRE. The proportion of 
CRE was approximately 10-fold higher among isolates 
from inpatients (3.5%) than among those from outpa-
tients (0.3%) (Table 1).
Proportions of CRE in different species are shown 
in Table 1. K. pneumoniae was the most affected 
species (proportion: 11.9%) and contributed to the 
majority of CRE (234 of 270, 86.7%). Lower CRE propor-
tions, but still higher than 2%, were observed among 
Enterobacter spp., Serratia marcescens, and Hafnia 
alvei. In Escherichia coli the proportion of CRE was very 
low (0.06%).
CRE were reported from 23 of the 25 participating labo-
ratories (Figure 1). Carbapenem-nonsusceptible iso-
lates of K. pneumoniae were detected at any of these 
23 laboratories, with proportions ranging from 1.2 to 
32.7% (mean: 11.5%) (Figure 1).
Carbapenem resistance mechanisms in 
carbapenem-resistant Enterobacteriaceae 
Carbapenemase production was detected in the major-
ity of CRE (85%) (Table 2). KPC-type enzymes were 
by far the most common (89.5% of carbapenemase 
producers). Other types of carbapenemases included 
VIM-1 and OXA-48 (9.2% and 1.3% of carbapenemase 
producers, respectively). KPC-type enzymes were only 
detected in K. pneumoniae and in one E. coli. VIM-
1, although much less prevalent, was detected in a 
wider variety of bacteria: K. pneumoniae, Klebsiella 
oxytoca, E. coli and Enterobacter cloacae. OXA-48 was 
only detected in three K. pneumoniae isolates (Table 
2). KPC-producers were detected in 21 of 25 centres, 
showing a countrywide distribution. VIM-1-producers 
were detected in six centres, while the three OXA-48-
producers were from three different centres (Figure 1). 
Other types of carbapenemases, including NDM, were 
not detected. 
table 1
Proportions of carbapenem-non-susceptible Enterobacteriaceae detected in the first countrywide survey, Italy, 15 May–30 
June 2011 (n=13,749)
Species Isolates from inpatients Isolates from outpatients All isolates
Total CRE (%) Total CRE (%) Total CRE (%)
Escherichia coli 3,844  4 (0.10) 4,765  1 (0.02) 8,609  5 (0.06)
Klebsiella pneumoniae 1,346 219 (16.3) 618 15 (2.4) 1,964 234 (11.9)
Klebsiella oxytoca 203 0 116  1 (0.86) 319  1 (0.31)
Enterobacter cloacae 361 15 (4.2) 144 0 505 15 (3.0)
Enterobacter aerogenes 147  4 (2.7) 68  2 (2.9) 215  6 (2.8)
Serratia marcescens 117  4 (3.4) 39  1 (2.6) 156  5 (3.2)
Proteus mirabilis 624  1 (0.16) 491 0 1,115  1 (0.09)
Citrobacter freundii 79 0 56  1 (1.8) 135  1 (0.74)
Hafnia alvei 24  2 (8.3) 8 0 32  2 (6.2)
Other species 409 0 290 0 699 0
Total 7,154  249 (3.5) 6,595  21 (0.32) 13,749  270 (2.0)
CRE: carbapenem-resistant Enterobacteriaceae.  
All collected isolates confirmed to be non-susceptible to imipenem (not considered for Proteeae) and/or meropenem and/or ertapenem 
according to the EUCAST breakpoints [26] were considered as CRE for the purposes of this study.
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Carbapenem-non-susceptible Klebsiella 
pneumoniae: proportion in clinical 
specimens, distribution in hospital 
wards, and carbapenem MICs
The overall proportion of carbapenem non-suscepti-
bility was approximately seven-fold higher in K. pneu-
moniae isolates from inpatients than in those from 
outpatients (16.3% versus 2.4%, Table 1). Considering 
isolates from inpatients, the proportion of carbapenem 
non-susceptibility was higher among bloodstream 
isolates than among isolates from other specimens 
(Table 3), revealing that carbapenem-non-susceptible 
K. pneumoniae strains circulating in Italy retained a 
remarkable potential for causing invasive infections. In 
the case of outpatients, carbapenem-non-susceptible 
isolates of K. pneumoniae were obtained only from 
urine, which was by far the most common specimen, 
and most of them were KPC-producers (Table 3).
Concerning the in-hospital distribution, 42.5% of the 
219 carbapenem-nonsusceptible K. pneumoniae from 
inpatients were from intensive care units (ICUs), while 
32.4% were from medical wards, 21.5% from surgical 
wards, and 3.6% from other areas.
Carbapenem MICs of the 234 carbapenem-nonsuscep-
tible K. pneumoniae are reported in Table 4. Virtually 
all isolates were resistant to ertapenem, while some 
were intermediate or susceptible to the other carbap-
enems. A susceptible or intermediate phenotype to 
imipenem and/or meropenem was observed with most 
of the VIM producers, with the OXA-48 producers and 
with the non-carbapenemase producers, while most of 
the KPC producers were resistant also to these drugs.
Molecular epidemiology and susceptibility to non-beta-
lactam agents of KPC-producing Klebsiella pneumoniae
To gather information on the molecular epidemiology 
of KPC-KP circulating in Italy, the 204 KPC-KP isolates 
were characterised by MLST and by PFGE genotyp-
ing, and their KPC allelic variants were determined by 
sequencing. 
table 2
Mechanisms of resistance in carbapenem-nonsusceptible isolates of Enterobacteriaceae, Italy, 15 May–30 June 2011 (n=270)
Species
Isolates
Carbapenemase Non-carbapenemase
Total (%) KPC VIM-1 OXA-48 Total (%)
Escherichia coli 5 2 (40.0) 1 1 0 3 (60.0)
Klebsiella pneumoniae 234 223 (95.3) 204 16 3 11 (4.7)
Klebsiella oxytoca 1 1 (100.0) 0 1 0 0 
Enterobacter cloacae 15 3 (20.0) 0 3 0 12 (80.0)
Othersa 15 0 0 0 0 15 (100.0)
Total 270 229 (84.8) 205 21 3 41 (15.2)
a Including Enterobacter aerogenes (n=6), Serratia marcescens (n=5), Proteus mirabilis (n=1), Citrobacter freundii (n=1), and Hafnia alvei (n=2).
table 3
Proportions of carbapenem-non-susceptible Klebsiella pneumoniae from different clinical sources, Italy, 15 May–30 June 
2011 (n=1,346)
Source Isolates from inpatientsa Isolates from outpatientsb
Total CNS-KP (%) Total CNS-KP (%)
Blood 179  40 (22.3) 7 0
Lower respiratory tract 219  40 (18.3) 38 0
Urine 647  93 (14.4) 503 15 (3.0)
Other 301  46 (15.3) 70 0
Total 1,346 219 (16.3) 618 15 (2.4)
CNS-KP: carbapenem-non-susceptible Klebsiella pneumoniae. 
a Mechanisms of resistance: KPC (n=190; 86%);VIM (n=15; 7%); OXA-48 (n=3; 2%); non-carbapenemase producer (n=11; 5%).
b Mechanisms of resistance: KPC (n=14; 93%); VIM (n=1; 7%).
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MLST revealed that most isolates belonged in CC 
258, either ST-258 or ST-512 (a single locus variant 
of ST-258), while a minority were ST-101. ST-258 and 
ST-512 isolates were detected in many centres, with 
an overall countrywide distribution, while ST-101 iso-
lates were detected in only two centres, where ST-512 
was also present (Figure 2). Isolates of ST-258 carried 
either blaKPC-2 or blaKPC-3 alleles, while those of ST-512 
and of ST-101 carried blaKPC-3 and blaKPC-2, respectively 
(Figure 2). 
PFGE genotyping revealed an oligoclonal population of 
KPC-KP, with a prevalent PFGE profile, named A, con-
sisting of several variants (A0 to A6) and including the 
isolates of CC-258. In particular, the A0, A4 and A5 vari-
ants included isolates of ST-512 producing KPC-3, while 
the A1 and A2 variants included isolates of ST-258 pro-
ducing KPC-3, and the A3 and A6 variants included iso-
lates of ST-258 producing KPC-2 (Figure 2). Each variant 
was detected in multiple centres (Figure 2), confirming 
the epidemic propensity of this lineage. An additional 
PFGE profile, named B and consisting of only a few vari-
ants (B0 to B2), included the isolates of ST-101 produc-
ing KPC-2 and was detected in two centres (Figure 2).
Susceptibility testing of the 204 KPC-KP against 
non-beta-lactam agents which often retain activity 
against these strains, revealed that 22.4% were resist-
ant to colistin, 20.9% were non-susceptible to tigecy-
cline, and 15.8% were non-susceptible to gentamicin. 
Concerning co-resistances, 1.5% of the KPC-KP were 
non-susceptible to all three drugs, while 6.4% were 
non-susceptible to tigecycline and colistin, 1% to 
gentamicin and colistin, and 2.7% to tigecycline and 
gentamicin. No association was detected between ST 
and non-susceptibility to colistin or tigecycline, while 
non-susceptibility to gentamicin was more frequent in 
isolates of ST-101 (85.8% versus 12.6% in ST-258 or 
10% in ST-512, p<0.05). 
Discussion
A rapid dissemination of carbapenem-non-susceptible 
K. pneumoniae has been reported in Italy since 2010 
[10,24]. Results of this cross-sectional survey, carried 
out in mid-2011, confirmed that CRE have undergone 
an epidemic diffusion in Italy, with a widespread dis-
tribution across the national territory (although with 
variable proportions in different areas), and that the 
phenomenon was mostly related with rapid dissemina-
tion of carbapenem-non-susceptible K. pneumoniae, 
while the contribution by CRE of other enterobacterial 
species was much more limited.
Production of KPC-type carbapenemases was the 
most prevalent carbapenem resistance mechanism. 
Production of other carbapenemases and non-carbap-
enemase-mediated mechanisms were also detected, 
but remained in the background. However, continuous 
surveillance should be enforced, considering a recent 
outbreak caused by NDM-1-producing K. pneumoniae 
[18]. 
Expansion of KPC-KP strains belonging to variants (ST-
258 and ST-512) of the hyperepidemic CC-258, detected 
for the first time in Italy in late 2008 [13], was responsi-
ble for a major part of the CRE epidemic in Italy. A similar 
table 4
Susceptibility of carbapenem-non-susceptible Klebsiella pneumoniae to various carbapenems, Italy, 15 May–30 June 2011 
(n=234) 
Resistance 
mechanism
Meropenem Imipenem Ertapenem
Range MIC50 MIC90 %S %R Range MIC50 MIC90 %S %R Range MIC50 MIC90 %S %R
KPC (n=204) 4 to >32 >32 >32 0 94
4 to 
>32 32 >32 0 96
16 to 
>32 >32 >32 0 100
VIM (n=16) 2 to >32 2 32 62 19
1 to 
>32 2 8 50 6
4 to 
>32 8 >32 0 100
OXA-48 (n=3) 1 to 8 1 1 66 0 0.5 to 8 1 1 66 0 >32 >32 >32 0 100
Non-carbapenemase 
(n=11)
0.25 
to 4 0.5 1 90 0
0.25 
to 1 0.5 1 100 0
1 to 
>32 8 32 0 90
Total CPE (n=223) 1 to >32 >32 >32 6 87
0.5 to 
>32 >32 >32 5 87
4 to 
>32 >32 >32 0 100
TOTAL (n=234)
0.25 
to 
>32
>32 >32 10 82
0.25 
to 
>32
32 >32 10 83 1 to >32 >32 >32 0 99
CPE: carbapenemase-producing Enterobacteriaceae; MIC: minimum inhibitory concentration; R: resistant; S: susceptible.
MICs in mg/L, interpreted according to EUCAST breakpoints [26]. Percentage of isolates with intermediate susceptibility not shown in the 
table.
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phenomenon was also observed in other countries and 
further underscores the propensity for dissemination 
of multi-resistant K. pneumoniae strains belonging 
to ST-258 and ST-512 [40-47]. Emergence of KPC-KP 
belonging to ST-101 was also observed, although 
only in two of the participating centres. This finding, 
along with recent reports of ST-101 isolates of KPC-KP 
from Italy, Brazil and the United States [21,42,48,49], 
emphasises the emerging role in dissemination of KPC 
of this clonal lineage which is also involved in the dis-
semination of other carbapenemases, such as OXA-
48 and OXA-181 [50,51] as well as extended-spectrum 
beta-lactamases [52,53]. 
Since aggressive infection control was shown to be 
effective in controlling the dissemination of KPC-KP 
[54-56], present results mandate for strong and 
prompt intervention in Italy. Implementation of infec-
tion control measures on a countrywide scale appears 
now to be necessary, in addition to the actions that 
have already been taken at local and regional level 
(the Italian public healthcare system has a typically 
regional organisation) with positive results. In a hos-
pital in Catania, Sicily, it was possible to control the 
spread of a KPC-3-producing K. pneumoniae clone with-
out closing the ICU, by applying a multimodal infection 
control programme [16]. The Emilia-Romagna region 
issued in July 2011 guidelines and protocols to moni-
tor and control the spread of carbapemenase-produc-
ing Enterobacteriaceae in all the healthcare structures 
of the region. The increasing trend of KPC-producing 
K. pneumoniae slowed down in the second half of 2011 
and early 2012, and in hospitals that had been able to 
implement all control activities the number of cases 
had a remained stable or showed a sustained decrease 
[57]. Dissemination of carbapenem-non-susceptible 
K. pneumoniae was not restricted to ICU settings, but 
affected all major hospital sectors. Although at least 
some of these patients could have been transferred 
from ICU settings, this propensity to dissemination on 
Figure 2
XbaI PFGE profiles of KPC-KP in combination with MLST results and KPC-type alleles, Italy, 15 May–30 June 2011 (n=204 )
PFGE: pulsed-field gel electrophoresis; KPC-KP: KPC-type carbapenemase-producing Klebsiella pneumoniae; MLST: multi-locus sequence 
typing.
DNA size standards for PFGE profiles are indicated at the bottom. Distribution by centres of different PFGE-types is also indicated: 1: Milan; 2: 
Varese; 3: Lecco; 4: Turin; 5: Novara; 6: Genoa; 7: Sanremo; 8: Verona; 9: Bolzano; 10-11: Modena; 12: Florence; 13: Siena; 14: Perugia; 15: 
Ancona; 16: Rome; 17: Pescara; 18: San Giovanni Rotondo; 19: Lecce; 20: Naples; 21: Avellino; 22: Cosenza; 23: Palermo; 24-25: Catania.
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multiple wards should be considered when planning 
infection control strategies.
Although cases and outbreaks of CRE have been 
reported in many European countries [6], only Greece, 
Cyprus and Italy have experienced such an extensive 
CRE epidemic to date. However, the phenomenon 
observed in these countries deserves considerable 
attention by public health authorities in Europe, con-
sidering the high mobility of people (tourists, workers, 
patients) within Europe, and the difficulties in contain-
ing the epidemic diffusion of CRE.
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